Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 289190
Licensor grants an option, the License Option, to acquire a worldwide, nonexclusive, or to the extent available, exclusive license, with the right to sublicense, under some or all of the Additional Patent Rights and the Additional Know-How to make, have made, use, develop, sell, offer for sale, have sold, import and export Products.
Licensed Compound means any Existing Compound or any Derivative. Any Licensed Compound shall also include any salt, metabolite, prodrug, constitutional or geometric isomer, regioisomer, stereoisomer including any enantiomer or diastereoisomer, salt form, hydrate, solvate, polymorph or other physical form of any such compound.
Bioisosteric Scaffold means any scaffold that is bioisosteric to a Licensor Agreement Scaffold and Controlled by Licensee.
Licensee is a multinational health care company that has expertise and capability in developing and marketing human pharmaceuticals and has research and development programs.
Farnesoid X receptor is a nuclear receptor that is encoded by the NR1H4 gene in humans.
XL335 targets the Farnesoid X Receptor (FXR) and has been shown to function as a bile acid receptor regulating genes involved in lipid, cholesterol and bile acid homeostasis. We have identified proprietary, potent and selective FXR ligands (a compound that binds to a receptor) that have good oral bioavailability and drug metabolism and pharmacokinetic properties. In rodent models of dyslipidemia, these compounds lowered triglycerides by decreasing triglyceride synthesis and secretion. In addition, they improved the high-density lipoprotein (HDL)/low-density lipoprotein (LDL) ratio and are anti-atherogenic (preventing the formation of lipid deposits in the arteries) in animal models of atherosclerosis. XL335 is also effective in models of cholestasis (a condition in which bile excretion from the liver is blocked), cholesterol gallstones and liver fibrosis. These data suggest that small molecule ligands targeting FXR should function as novel therapeutic agents for treating symptoms and disease states associated with metabolic syndrome as well as certain liver disorders.
IPSCIO Record ID: 7419
The Licensor granted the Licensee an exclusive, worldwide, royalty-bearing license to MBX-8025 and certain other PPAR compounds (the PPAR Products) with the right to grant sublicenses to third parties to make, use and sell such PPAR Products.
MBX-8025 is a selective agonist (a substance that stimulates a response by binding to a receptor) for the peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes involved in lipid storage and transport (particularly in fatty acid oxidation) and insulin signaling and sensitivity. In preclinical studies in rodents, dogs and primates, MBX-8025 demonstrated a variety of beneficial effects on the lipid profile and other metabolic parameters. MBX-8025 treatment increased peripheral oxidation of fatty acids leading to reduced levels of triglycerides (TGs) and low-density lipoprotein (LDL), while raising high-density lipoprotein (HDL). MBX-8025 inhibited fat mass accumulation, resulting in attenuation of body weight gain in rodent models of obesity.
MBX-8025 has potential therapeutic application for disorders linked to deficits in lipid storage, handling and utilization, many of which result in metabolic disorders. To date, it has been in development as a first-in-class treatment that effectively addresses all three lipid disorders associated with mixed dyslipidemia (abnormal lipid levels in the blood) as well as a majority of the cardiovascular risk factors that define metabolic syndrome. The future development program will focus on high unmet need indications in dyslipidemia as well as in high unmet need specialty and orphan diseases.
The 8-week Phase 2 study investigated MBX-8025 at doses of 50 or 100 mg/day in moderately obese patients with mixed dyslipidemia. The study demonstrated that treatment with MBX-8025 led to significant reductions in total LDL (~20%) and selective depletion of the small dense atherogenic (promotion of arterial plaque formation) LDL particles, resulting in an exceptional improvement in the LDL particle size profile. It also decreased TGs (~30%) and raised HDL (~12%). This unique combination of effects significantly decreased the atherogenic risk of patientsâ€™ lipid profile. When administered in combination with atorvastatin (LipitorÂ®), MBX-8025 provided a comprehensive improvement in all lipid and cardiovascular risk parameters without side effects seen in other combination lipid therapies.
In addition, MBX-8025 addressed other aspects of metabolic syndrome, including improvements in insulin sensitivity and trends toward decreased waist circumference and body fat. Over half of the patients that entered the Phase 2 study meeting the criteria for metabolic syndrome no longer met the criteria at the end of the study.
The product seladelpar is for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver. Seladelpar is a potent and selective agonist of PPARd, a nuclear receptor that regulates genes important for lipid, bile acid/sterol and glucose metabolism and for inflammation in liver and muscle.
Under the terms of the agreement, the Licensee has full control and responsibility over the research, development and registration of any PPAR Products and is required to use diligent efforts to conduct all such activities.
The Licensee shall grant the Licensor a worldwide, exclusive, irrevocable license under the agreement in all information that is controlled, developed or acquired by the Licensee which relates to a PPAR compound or PPAR product and in all patents that are filed.
IPSCIO Record ID: 372521
Licensee has the right to develop and commercialize the PET Ligand as set forth.
Licensor patents and technology relate to Imidazole Derivatives. The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).
The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.
The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.
The term EVT 101 shall mean xO-4394127.
The term EVT 103 shall mean xO-0717626.
The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimerâ€™s disease, neuropathic pain and Parkinsonâ€™s Disease.
IPSCIO Record ID: 203296
Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
Gene Expression Modulation by Small-molecules (GEMS) is PTCâ€™s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.
Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.
IPSCIO Record ID: 249742
Designated Compound means BMS-201,038; prodrugs or metabolites of BMS-201,038, to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds; furthermore, in the case of a prodrug or metabolite as referred to above, the compound in question will constitute a Designated Compound hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of BMS-210,038 within the Field of Use.
The University completed a Phase II clinical trial of lomitapide for the treatment of patients with called homozygous familial hypercholesterolemia, or HoFH.
Licensee's lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor, or MTP-I, which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. Licensee is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. These patients are at very high risk of experiencing life threatening events at an early age as a result of extremely elevated cholesterol levels in the blood. Licensee believe that lomitapide, either on a stand-alone basis or in combination with other drugs, has the potential to help these patients achieve recommended target levels of low-density lipoprotein cholesterol, or LDL-C.
IPSCIO Record ID: 182114
Diacylglycerol O-acyltransferase 1 is an enzyme that in humans is encoded by the DGAT1 gene.
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
IPSCIO Record ID: 249743
Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.
Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both. Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.
IPSCIO Record ID: 383572
Compound means an Agents prodrug that utilizes the Licensor Liver Targeting Prodrug Technology and is discovered or Developed by or for the account of a Party pursuant to such Partys performance of its obligations under this Agreement.
Agent means any of the following natural omega-3 fatty acids
— EPA (i.e., icosapentaenoic acid) or an EPA ester,
— DHA (i.e., docosahexaenoic acid) or a DHA ester,
— a combination of EPA (or an EPA ester) with DHA (or a DHA ester) or,
— any of the individual omega-3 fatty acids or a complex mixture of the omega-3 fatty acids contained (as of the Effective Date) within EpanovaTM.
Licensor Liver Targeting Prodrug Technology means Licensors program for the development of a liver-specific drug targeting technology for chemically modifying the molecule to render it inactive until the modification is cleaved off by a liver-specific enzyme, including all related intellectual property and other related rights of Licensor, and any and all related clinical and non-clinical data compiled by Licensor, in each case arising from the Licensors operation of such program.
The patents include
Prodrug compounds and uses for Liver Targeting;
Prodrug compounds and uses thereof; and,
Prodrug compounds and their uses thereof.
IPSCIO Record ID: 294283
Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.
BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.
BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.
Licensed Compound shall mean BT16.
The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.
BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.
Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia. Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.
IPSCIO Record ID: 324330
The German Licensor grants to the Licensee of Ireland a joint ownership interest in the Licensor Patent Rights and Trademarks (Joint Ownership Interest) and a non-assignable right and license to use the Licensor IPR Package (Licensors know-how and Intellectual Property rights)
to Commercialize the Product in the Territory;
to Manufacture in any country the quantities of Product required for Commercialization in the Territory; and
to Develop the Product for Commercialization in the Territory.
With this amendment, Licensee now has a joint ownership interest under the Licensor Patent Rights and the Licensor Trademarks to carry out development, manufacturing, registration and commercialization of the Product in the Territory.
Patents are or relate to Growth Hormone Secretagogues; Methods and kits to diagnose Growth Hormone Deficiency; Method of Assessing Growth Hormone Deficiency Comprising Oral Administration of a Macimorelin Containing Composition and Collecting One or Two Post-administration Samples; Use of Macimorelin in Assessing Growth Hormone Deficiency in Children; A novel peptide-mimetic GH secretagogue with potent and selective GH-releasing activity in man by Broglio et al; Targeting the Ghrelin Receptor; and, GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
API means the active pharmaceutical ingredient macimorelin acetate, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing.
Trademark means the Macrilen trademark registered in the Territory and any accompanying logos, trade names, trade dress and/or other indicia relating to the Product Controlled by Licensor.
Macimorelin (INN), or Macrilen (trade name) is a drug being developed for use in the diagnosis of adult growth hormone deficiency.
IPSCIO Record ID: 27002
Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoprotein (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoprotein (HDL), (see apoA-1 Milano).
IPSCIO Record ID: 249765
For License to Compounds, Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to research, develop, make, have made, import, export and use the Selected Compounds, and Active Compounds, Improved Active Compounds and Preliminary Compounds of the same Chemotype as such Selected Compounds, Designated Compounds and Derivative Compounds, for research purposes and to develop Licensed Products.
This agreement also includes non-exclusive grants for research.
Preliminary Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd ~ 1 OÂµM) or such other binding affinity threshold for a specific Target as shall be agreed upon by the parties in writing.
ALIS means the Automated Ligand Identification System, an automated, ultrahigh throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.
OSCD means Quantisized Surface Complimentary Diversity, a model proprietary to Licensor, in terms of which discrete chemical compliments to the surfaces of a Target are defined.
Licensor Know-How means all proprietary information, data and know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries, NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, approved Active Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or Licensed Products together with, where applicable, any analogs, derivatives or fragments thereof.
Chemotype means a family or group of Compounds closely structurally related to one or more Active Compounds.
Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.
IPSCIO Record ID: 211864
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient. The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.
This agreement pertains to drug discovery.
IPSCIO Record ID: 309678
Licensor has expertise and proprietary technical information and know-how relating to application of protein folding, trafficking and clearance-based, small molecule therapeutics for the treatment of diseases and is committed to the research and development of therapeutic methods and products for the treatment of diseases.
Licensed Product means any product for use in the Field that contains a Development Compound (or any pharmaceutically acceptable radioisomers, stereoisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, prodrugs, and ester forms thereof) as an Active Ingredient.
Development Compound means an Active Compound in a Hit Series or derived from a Hit Series that is designated by Licensee, in Licenseeâ€™s sole discretion, for further Development by Licenseeâ€™s exercise of its Development Option for that Active Compound in accordance with this agreement (Development Compounds). For avoidance of doubt, Development Compound includes Co-Developed Compounds.
Active Compound means a Compound that is shown in functional, in vitro testing using living human cells, and appropriately counter-screened or otherwise verified, to satisfy the threshold criteria set forth in the Research Plan for an effect as a UPR Modulator in the Indication specified by the Research Plan for the relevant Project.
The Licensorâ€™s DRTâ„¢ platform utilizes functionally pertinent assays and disease relevant models to identify highly translatable therapies associated with the modulation of protein homeostasis pathways within the cell.
The proteostasis network (PN) comprises the intricately regulated interplay of signaling processes and molecular machines involved in the synthesis, folding, and clearance of the diverse spectrum of proteins comprising the folded, native proteome.
The collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. Stress induced by accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many diseases which are now recognized as protein conformational diseases, including genetic diseases, neurodegenerative diseases, and retinal degenerative diseases. Selective modulation of the UPR pathway in non-clinical investigations improved the stress response and restored function, suggesting that it can be beneficial as potential novel disease-modifying therapies for multiple diseases with high unmet medical needs.
A novel approach to drug discovery will enable rapid discovery and development of therapies for important unmet medical needs. The collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. Stress induced by accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many diseases which are now recognized as protein conformational diseases, including genetic diseases, neurodegenerative diseases, and retinal degenerative diseases. Selective modulation of the UPR pathway in non-clinical investigations improved the stress response and restored function, suggesting that it can be beneficial as potential novel disease-modifying therapies for multiple diseases with high unmet medical needs.
Licensee is engaged in the research, development, production, marketing and sale of therapeutics and is interested in the development and commercialization of pharmaceutical products for treatment through regulation of the proteostasis network with a focus on modulations of the human unfolded protein response (UPR).
IPSCIO Record ID: 253904
The know-how and patents include screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.
Licensed Product(s) means any product which includes a Designated Compound or any derivatives, improvements and components thereof; and the development, manufacture, use, or sale.
Licensor Library includes ALIS, the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to the Licensor that is used to identify multiple classes of chemical ligands against target protein.
IPSCIO Record ID: 352729
Upon â€™s Licensees exercise of the Option, Licensor grants a worldwide, irrevocable, exclusive license, with the right to sublicense, under the Licensors Patents, Know-How and interest in the Joint Inventions and Joint Patents, to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory, and a worldwide, irrevocable, non-exclusive license, with the right to sublicense, under the Licensor Technical Information to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory, collectively the License.
License Grant Upon Expiration of the Royalty Term. SGI hereby grants to GSK a worldwide, non-exclusive fully paid-up license, with the right to sublicense, under the SGI Know-How and SGI Technical Information to continue to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory upon Expiration in Entirety.
CLIMBâ„¢ or CLIMB means that certain proprietary process, comprising hardware, software, bench chemistry, synthesis, analysis and testing used by Licensor for the purpose of the discovery, evaluation and development of new chemical entities.
Compound means any inhibitor of DNA methyltransferases, including DNA methyltransferase 1 (DNMTÂ·1) and/or DNA methyltransferase 3 (DNMT-3) owned or Controlled by SGI, as well as any pro-drugs of such compounds, any metabolites of such compounds having DNMT target activity, all stereoisomers of such compounds including salts, and any solvates or polymorphs of such compounds. Compound will not include Decitabine (S-aza-2 – deoxycytidine) and all stereoisomers, salts, polymorphs, esters and acids of Decitabine, Vidaza'â€¢, or analogues of azacitidine. Compound will also not include polynucleosides or polynucleotides comprising at least one base of cytidine or its derivatives or analogues, including Decitabine.
Epigenetics refers to the regulation of genes with mechanisms other than changes to the underlying DNA sequence. Epigenetic processes are widely believed to play a central role in the development and progression of almost all cancers.
IPSCIO Record ID: 273416
Licensed Patents means any and all Patent Rights which Licensor Controls in any country of the Territory, having one or more Valid Claims Covering the Licensed Compound or Product in the Field and which are reasonably necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory. Licensed Patents includes the Patent Rights set forth below
U.S. Patent 6312662 – Prodrugs phosphorus-containing compounds
U.S. Patent 6946115 – Prodrugs for phosphorus-containing compounds
U.S. Patent 6752981 – Prodrugs for liver specific drug delivery
Licensed Technology means all HepDirect Technology on the Closing Date or during the Term, which are necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory. By way of clarification, Licensed Technology includes all such HepDirect Technology conceived or acquired in whole or in part by Licnesor on or after the Closing Date including the items set forth in the agreement.
Licensed Compound means all forms of MB6866 as identified (at times known as remofovir and now known as pradefovir) including any complexes, chelates, clathrates, acids, bases, esters, salts, isomers, stereoisomers, enantiomers, pro-drug form, metabolite, hydrate, solvate, polymorph, and crystalline forms thereof, or any Substitute Compound substituted in accordance with Article III, and its various forms including salts and prodrugs.
IPSCIO Record ID: 291117
— an exclusive license for the Field in the Territory under the Licensed Patents; and
— an exclusive license for the Field to use the Know-How in the Territory; for the sole and exclusive purpose of developing, making, having made, importing, using and selling Licensed Products in the Territory, including the right to grant sublicenses.
Licensed Patents are titled and related to Liposome Compositions and Methods for the Treatment of Atherosclerosis.
The European patents claim methods for treatment of atherosclerosis using liposomes. The U.S. patent applications claim liposome compositions and methods for treatment of disease, including atherosclerosis. The European patents expires in 2011.
Atherosclerosis refers to the buildup of fats, cholesterol and other substances in and on your artery walls (plaque), which can restrict blood flow. The plaque can burst, triggering a blood clot. Although atherosclerosis is often considered a heart problem, it can affect arteries anywhere in your body.
— For Improvements, human and veterinary therapeutics, but limited to products that use or include Large Unilammelar Vesicles (LUVS) as a therapeutic agent which are not associated with any other therapeutic agent other than an apoprotein, the Improvements Field;
— For Know-How, human and veterinary therapeutics, but limited to products that use or include Large Unilammelar Vesicles (LUVS) as a therapeutic agent which are not associated with any other therapeutic agent other than an apoprotein, the Know-How Field;